Phase II trial of subcutaneous PL 3994 for the treatment of acute decompensated heart failure.
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2015
At a glance
- Drugs PL 3994 (Primary)
- Indications Decompensated heart failure
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Palatin Technologies
- 28 Sep 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jan 2016, as per Palatin media release.
- 11 Mar 2008 New trial record.